Recombinant Human ITIH1 His-tag Protein, CF

Recombinant Human ITIH1 His-tag Protein, CF Summary

Product Specifications

Product Datasheets

Carrier Free

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

Background: ITIH1

Inter-alpha-trypsin inhibitor heavy chain 1 (ITIH1) is a heavy chain (HC) member of the ITIH family that is synthesized in the liver and circulates in the plasma (1). ITIH1 contains a signal sequence, propeptide, and a conserved von-Willebrand type A domain as in other HCs in the family. ITIH1 also includes a c-terminal extension multicopper oxidase domain, present in ITIH3 as well, that is trimmed to reveal a c-terminal aspartic acid residue that enables crosslinking of the HC to chondroitin sulfate (CS) (1,2). ITIH1 represents the HC1 component of Inter-alpha -inhibitor.  Inter-alpha -inhibitor is a protease inhibitor composed of three subunits (HC1, HC2, and bikunin), which are linked together via a CS moiety (1,3). ITIH1 can alternatively be associated with hyaluronan (HA) to form the Serum-derived hyaluronan associated protein (SHAP)-hyaluronan (HA) complex known to assist in stabilizing HA-rich extracellular matrices in the context of inflammatory processes and ovulation (3,4).  Tumor necrosis factor-stimulated gene-6 (TSG-6) has high affinity for heavy chains and plays an important role in the transfer of HC to HA matrix by forming a TSG-6:HC complex intermediate required for the transfer (4,5). Inter-alpha -inhibitor heavy chains potentiate CD-44-mediated leukocytes adhesion to hyaluronan substratum and recruit immune cells to sites of inflammation (6).  The SHAP-HA complex was found to be upregulated in patients at various clinical stages of chronic hepatitis (CH), liver cirrhosis (LC), and hepatocellular carcinoma (HCC) caused by infection with the hepatitis C or hepatitis B virus (7).  ITIH1 has been shown to increase cell attachment and reduce the number of metastases in an antitumoral role (8).